Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming November 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Savara Inc. (“Savara” or the “Company”) (
NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”).
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Savara Inc. (“Savara” or the “Company”) (
NASDAQ: SVRA).
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (
NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRANEW YORK - November 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRANEW YORK - November 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
Lost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Lost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyNEW YORK - November 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Savara Inc. (
NASDAQ: SVRA) of a class action securities lawsuit.
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Savara To Contact Him Directly To Discuss Their Options
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences.
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (
NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at $4.20 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors that so chose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant. The aggregate gross proceeds to Savara from the offering were approximately $149.5 million before deducting underwriting discounts and commissions and other offering expenses.
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 7, 2025 - SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SAVARA CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before November 7thBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options
SVRA Deadline: Rosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (
NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). Savara is a clinical-stage biopharmaceutical company.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (
NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRANEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. (“Savara” or the “Company”) (
NASDAQ: SVRA) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 25-cv-05147, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Savara securities between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 7, 2025 - SVRASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 7,142,857 shares of common stock at a price of $4.199 per pre-funded warrant, in each case, before deducting underwriting discounts and commissions, for total gross proceeds of $130.0 million. All of the securities to be sold in the offering are being sold by Savara. Savara also granted the underwriters a 30-day option to purchase up to an additional 4,642,857 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 31, 2025, subject to the satisfaction of customary closing conditions.
